[1] |
Ständer S. Atopic dermatitis[J]. N Engl J Med, 2021,384(12):1136⁃1143. doi: 10.1056/NEJMra2023911.
|
[2] |
Dong WL, An J, Yu M, et al. The prevalence and year lived with disability of atopic dermatitis in China: findings from the global burden of disease study 2019[J]. World Allergy Organ J, 2021,14(11):100604. doi: 10.1016/j.waojou.2021.100604.
|
[3] |
Cheng J, Wu JJ, Han G. Epidemiology and characterization of atopic dermatitis in East Asian populations: a systematic review[J]. Dermatol Ther (Heidelb), 2021,11(3):707⁃717. doi: 10. 1007/s13555⁃021⁃00516⁃w.
|
[4] |
Laughter MR, Maymone M, Mashayekhi S, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990⁃2017[J]. Br J Dermatol, 2021,184(2):304⁃309. doi: 10.1111/bjd.19580.
|
[5] |
Wang X, Li LF, Zhao DY, et al. Prevalence and clinical features of atopic dermatitis in China[J]. Biomed Res Int, 2016,2016:2568301. doi: 10.1155/2016/2568301.
|
[6] |
Guo Y, Li P, Tang J, et al. Prevalence of atopic dermatitis in Chinese children aged 1 - 7 ys[J]. Sci Rep, 2016,6:29751. doi: 10.1038/srep29751.
|
[7] |
UpToDate. Atopic dermatitis (eczema): pathogenesis, clinical manifestations, and diagnosis[EB/OL].(2022⁃9⁃28)[2023⁃7⁃18]. https://www.uptodate.com/contents/atopic⁃dermatitis⁃eczema⁃ pathogenesis⁃clinical⁃manifestations⁃and⁃diagnosis.
|
[8] |
Langan SM, Irvine AD, Weidinger S. Atopic dermatitis[J]. Lancet, 2020,396(10247):345⁃360. doi: 10.1016/S0140⁃6736(20)31286⁃1.
|
[9] |
World Health Organization. WHO handbook for guideline development. 2nd Ed [M/OL]. (2014⁃12⁃18)[2023⁃07⁃18]. https://www.who.int/publications/i/item/9789241548960.
|
[10] |
陈耀龙, 杨克虎, 王小钦, 等. 中国制订/修订临床诊疗指南的指导原则(2022版)[J]. 中华医学杂志, 2022,102(10):697⁃703. doi: 10.3760/cma.j.cn112137⁃20211228⁃02911.
|
[11] |
Brouwers MC, Kho ME, Browman GP, et al. AGREEⅡ: advancing guideline development, reporting and evaluation in health care[J]. CMAJ, 2010,182(18):E839⁃842. doi: 10.1503/cmaj.090449.
|
[12] |
杨楠, 赵巍, 潘旸, 等. 针对临床实践指南科学性、透明性和适用性的评级工具研发[J]. 中华医学杂志, 2022,102(30):2329⁃2337. doi: 10.3760/cma.j.cn112137⁃20220219⁃00340.
|
[13] |
Guidelines International Network (GIN). GIN PUBLIC Toolkit: patient and public involvement in guidelines[M/OL]. [2022⁃11⁃3]. https://g⁃i⁃n.net/wp⁃content/uploads/2021/04/GIN⁃TOOLKIT⁃COMBINED⁃FINAL⁃2015.pdf
|
[14] |
陈耀龙, 荀杨芹, 李博, 等. 如何制订患者指南[J]. 协和医学杂志, 2020,11(4):453⁃458. doi: 10.3969/j.issn.1674⁃9081.2020. 04.017.
|
[15] |
陈耀龙, 马艳芳, 周奇, 等.谁应该参与临床实践指南的制订?[J]. 协和医学杂志, 2019,10(5):524⁃530. doi: 10.3969/j.issn.1674⁃9081.2019.05.017.
|
[16] |
Ma LL, Wang YY, Yang ZH, et al. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?[J]. Mil Med Res, 2020,7(1):7. doi: 10.1186/s40779⁃020⁃00238⁃8.
|
[17] |
Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ, 2008,336(7650):924⁃926. doi: 10. 1136/bmj.39489.470347.AD.
|
[18] |
中华医学会儿科学分会临床药理学组, 中华医学会儿科学分会呼吸学组, 刘恩梅, 等.中国儿童咳嗽指南(2021患者版)[J].儿科药学杂志, 2021,27(S1):17⁃22. doi: 10.13407/j.cnki.jpp.1672⁃108X.2021.S1.009.
|
[19] |
Zhang Y, Coello PA, Brożek J, et al. Using patient values and preferences to inform the importance of health outcomes in practice guideline development following the GRADE approach[J]. Health Qual Life Outcomes, 2017,15(1):52. doi: 10.1186/s12955⁃017⁃0621⁃0.
|
[20] |
刘辉, 王华, 刘云兰, 等. 中国儿童消化道异物管理指南(患者与公众版,2022)计划书[J]. 中国实用儿科杂志, 2022,37(2):81⁃87.
|
[21] |
Chen Y, Yang K, Marušic A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement[J]. Ann Intern Med, 2017,166(2):128⁃132. doi: 10.7326/M16⁃1565.
|
[22] |
王平, 周奇, 赵俊贤, 等. 临床实践指南基层版报告规范的研发[J].中国全科医学, 2023,26(13):1543⁃1550. doi: 10.12114/j.issn.1007⁃9572.2023.0043.
|
[23] |
Wang X, Chen Y, Akl EA, et al. The reporting checklist for public versions of guidelines: RIGHT⁃PVG[J]. Implement Sci, 2021,16(1):10. doi: 10.1186/s13012⁃020⁃01066⁃z.
|
[24] |
周奇, 王小琴, 姚亮, 等. 临床实践指南更新的若干关键问题[J]. 中国循证儿科杂志, 2016,11(5):392⁃397. doi: 10.3969/j.issn.1673⁃5501.2016.05.016.
|
[25] |
Ghazal S, Ridha Z, D′Aguanno K, et al. Treatment guidelines for atopic dermatitis since the approval of dupilumab: a systematic review and quality appraisal using AGREE⁃Ⅱ[J]. Front Med (Lausanne), 2022,9:821871. doi: 10.3389/fmed.2022.821871.
|
[26] |
叶城斌, 邹颖. 不同国家及地区特应性皮炎治疗指南的比较[J]. 中国皮肤性病学杂志, 2020,34(11):1331⁃1336,1340. doi: 10.13735/j.cjdv.1001⁃7089.202003205.
|